Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 May 2008, Vol. 111, No. 10, pp. 4841-4851.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nimer, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nimer, S. D.
Related Collections
Right arrow Hematopoiesis and Stem Cells
Right arrow Neoplasia
Right arrow Free Research Articles
Right arrow ASH 50th Anniversary Reviews
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

ASH 50th Anniversary Logo
ASH 50TH ANNIVERSARY REVIEW

Myelodysplastic syndromes

Stephen D. Nimer1

1 Division of Hematologic Oncology and Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY

There has been a remarkable explosion of knowledge into the molecular defects that underlie the acute and chronic leukemias, leading to the introduction of targeted therapies that can block key cellular events essential for the viability of the leukemic cell. Our understanding of the pathogenesis of the myelodysplastic syndromes (MDSs) has lagged behind, at least in part, because they represent a more heterogeneous group of disorders. The significant immunologic abnormalities described in this disease, coupled with the admixture of MDS stem or progenitor cells within the myriad types of dysplastic and normal cells in the bone marrow and peripheral blood, have made it difficult to molecularly characterize and model MDS. The recent availability of several, effective (ie, FDA-approved) therapies for MDS and newly described mouse models that mimic aspects of the human disease provide an opportune moment to try to leverage this new knowledge into a better understanding of and better therapies for MDS.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
R. M. Stone
How I treat patients with myelodysplastic syndromes
Blood, June 18, 2009; 113(25): 6296 - 6303.
[Full Text] [PDF]


Home page
NEJMHome page
F. Delhommeau, S. Dupont, V. D. Valle, C. James, S. Trannoy, A. Masse, O. Kosmider, J.-P. Le Couedic, F. Robert, A. Alberdi, et al.
Mutation in TET2 in Myeloid Cancers
N. Engl. J. Med., May 28, 2009; 360(22): 2289 - 2301.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Ades, S. Boehrer, T. Prebet, O. Beyne-Rauzy, L. Legros, C. Ravoet, F. Dreyfus, A. Stamatoullas, M. Pierre Chaury, J. Delaunay, et al.
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study
Blood, April 23, 2009; 113(17): 3947 - 3952.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Y. Follo, C. Finelli, C. Clissa, S. Mongiorgi, C. Bosi, G. Martinelli, M. Baccarani, L. Manzoli, A. M. Martelli, and L. Cocco
Phosphoinositide-Phospholipase C {beta}1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia
J. Clin. Oncol., February 10, 2009; 27(5): 782 - 790.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
N. S. Young
Paroxysmal nocturnal hemoglobinuria and myelodysplastic sydromes: clonal expansion of PIG-A-mutant hematopoietic cells in bone marrow failure
Haematologica, January 1, 2009; 94(1): 3 - 7.
[Full Text] [PDF]


Home page
BloodHome page
C. N. Abboud
Unlocking the dysplasia puzzle
Blood, October 15, 2008; 112(8): 3005 - 3006.
[Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020